Cancers of urinary system, prevalence, demographic
- Authors: Tolou Ghamari Z.1,2, Mazdak H.1,2
-
Affiliations:
- Isfahan Kidney Transplantation Research Center
- Isfahan University of Medical Sciences
- Issue: No 6 (2019)
- Pages: 74-77
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312360
- DOI: https://doi.org/10.18565/urology.2019.6.74-77
- ID: 312360
Cite item
Open Access
Access granted
Abstract
Background: The aim of this study was to clarify period prevalence (PP) and incidence associated to urinary system cancers in Isfahan Province/Iran. Methods: Data from 2011 to 2015 was obtained from the Isfahan Cancer Registry. The location of cancers was distinguished by the related established topography code (C64-C68). Period prevalence (PP) was calculated and expressed per 100000persons. Results: There were 2117 patients with urinary system cancers. The mean age ± SD was 63.6±14.9 years old, that in 62% ranged between 20 and 70years old. For total population the PP was calculated as 42. 5 per 100000persons. This value was corresponded to PP of 66.4 for males and 17.9 for females (p<0.001). The total PP was corresponded to values of 33.2 for bladder, 8.1 for kidney, 0.42 for renal pelvis, 0.36 for ureter and 0.38 for other unspecified related organs. Of these populations the estimated living cases corresponded to the 368females and 1513 males. Conclusion: The PP for urinary system cancers in male population was 3.7 times higher than females. There was a 23.2% increase in the Irs over the study period. These findings highlighted the advantage of further strategy base-research toward pharmacotherapy and surgery management of such patients.
Keywords
Full Text
About the authors
Z. Tolou Ghamari
Isfahan Kidney Transplantation Research Center; Isfahan University of Medical Sciences
Email: toloeghamari@pharm.mui.ac.ir
Isfahan, Iran
H. Mazdak
Isfahan Kidney Transplantation Research Center; Isfahan University of Medical SciencesIsfahan, Iran
References
- Yaxley J.P. Urinary tract cancers: An overview for general practice. J Family Med Prim Care 2016;5(3): 533-538.
- Aydin S, Yiicel Boz M. Rapid changes in the incidence of urinary system cancers in Turkey. Turk J Urol. 2015;41(4): 215-220.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013, CA Cancer J Clin 2013;63(1):11-30.
- Miyazaki J, Nishiyama H. Epidimiology of urothelial carcinoma. Int J Urol. 2017;24(10):730-734.
- Piaton E, Advenier AS, Carre C, Decaussin-Petrucci M, Mege-Lechevallier F, Hutin K,Nennig C, Colombel M, Ruffion A. p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up. Cancer. 2017;125(7):552-562.
- Bailey GC, Boorjian SA, Ziegelmann MJ, Westerman ME, Lohse CM, Leibovich BC, Cheville JC, Thompson RH. Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma. BJU Int. 2017;119(4):585-590.
- Zhang Y, Xu T, Wang Y, Zhang H, Zhao Y, Yang X, Cao Y, Yang W, Niu H. Prognostic Role of Lactate Dehydrogenase Expression in Urologic Cancers: A Systematic Review and Meta-Analysis. Oncol Res Treat. 2016;39(10):592-604. Epub 2016 Sep 12.
- Moch H. The WHO/ISUP grading system for renal carcinoma. Pathologe. 2016;37(4):355-60.
- Sadowski DJ, Geiger SW, Mueller GS, Zahnd WE, Alanee SR, McVary KT. Kidney Cancer in Rural Illinois: Lower Incidence Yet Higher Mortality Rates. Urology. 2016;94:90-95.
- Yee CH, Ng CF. Urological malignancy in Hong Kong: the trend and the practice. Jpn J Clin Oncol. 2015;45(12):1103-06.
- Akbari M, Naghibzadeh-Tahami A, Khanjani N, Baneshi MR, Kamali E, Hesampour M, Nazemzadegan B, Haghdoost AA. Opium as a Risk Factor for Bladder Cancer: A Populationbased Case-control Study in Iran. Arch Iran Med. 2015;18(9):567-71.
- Mazdak H, Tolou Ghamari Z. Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran. Arab J Urol. 2018;16(2):206-210.
- Tolou Ghamari Z. Prevalence of lung cancer in Isfahan Province, Iran. J Egypt Natl Canc Inst. J Egypt Natl Canc Inst. 2018;30(2):57-59.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, etal. (2010) GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010.
- Yang Y, Xie L, Zheng jl, Tan YT, Zhang W, Xiang YB. Incidence Trends of Urinary Bladder and Kidney Cancers in Urban Shanghai, 1973-2005. PLoS One. 2013;8(12):e82430. Published online 2013 Dec 4.
- Malekmakan L, Khajehdehi P,Pakfetrat M, Malekmakan A, Mahdaviazad H. Prevalence of Chronic Kidney Disease and Its Related Risk Factors in Elderly of Southern Iran: A Population-Based Study. ISRN Nephrology. Volume 2013 (2013), Article ID 427230, 6 pages.
- Woodford C, Yao C. Essential Med Notes 2013. Toronto: Toronto Notes for Medical Students Inc; 2013.
- Australian Institute ofHealth and Welfare. Cancer Survival and Prevalence in Australia: Period Estimates from 1982 to 2010. Canberra: Australian Institute of Health and Welfare;2012.
- Prithwish De, Michael C. Otterstatter, Robert Semenciw, Larry F. Ellison, Loraine D. Marrett, and Dagny Dryer. Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986-2007. Cancer Causes Control. 2014;25(10):1271-1281.
Supplementary files
